SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff and repeated tests of its yearly lows are drawing attention amid concerns about heavy debt, costly financing, refinancing needs and insider selling, alongside broader doubts about AI-infrastructure spending. Traders are split: bears see financing risks as a threat to growth, while bulls point to its backlog and AI partnerships and view the selloff as overdone; analyst upgrades and ARKs buying have not dispelled skepticism.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is rebounding alongside semiconductor stocks after a steep, extended selloff, drawing dip buyers who see oversold conditions and continued AI-chip demand as support for a recovery. Others warn the bounce may be temporary, citing concerns about AI investment returns and debt, market uncertainty, and upcoming chip-sector earnings.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is drawing attention amid a semiconductor selloff, with traders focused on CEO Hock Tans warning that some AI investing resembles gambling and his comments about capital constraints. The remarks and worries about AI spending and financing have fueled bearish sentiment, while other traders see the pullback as a buying opportunity based on Broadcoms AI-chip growth; many also complain that the stock has lagged semiconductor peers.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is drawing attention over concerns that its debt-funded AI data-center buildout and heavy capital spending could strain cash flow, amplified by widening credit-risk indicators and broader jitters around AI infrastructure financing. Traders are split between fears that spending and customer concentration pose serious risks and the view that Oracles cloud demand and backlog can eventually justify the investment, with some buying the selloff.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a prolonged post-IPO selloff, with traders citing lockup expirations and insider-share supply, a TD Cowen price-target cut, and concerns about OpenAI customer concentration, scaling, and Nvidia competition. Bears see continued selling pressure, while bulls argue the decline is overdone and point to Cerebras AI-chip technology and backlog.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid a volatile AI and semiconductor rebound, as traders debate whether credit strains at AI infrastructure firms such as CoreWeave and uncertain returns on data-center spending could undermine chip demand. Dip buyers see continued AI demand and upcoming hyperscaler earnings and GTC commentary as reasons for confidence, while skeptics warn that the rally may fade.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Discussion centers on Starknets quantum-resistance narrative and the possibility of moving from an Ethereum L2 to an independent L1, alongside claims of a quantum-resistant Bitcoin transaction test on mainnet. Bulls see the technology and Bitcoin/privacy applications as catalysts, while skeptics point to past dilution, token unlocks and sharp price swings.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas large equity offering has pressured shares, with traders citing dilution even as the capital is intended to support expansion. The selloff is being debated against the bullish AI and data-center demand outlook, prompting dip-buying while others remain concerned about volatility and the stocks valuation.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Scott Kirbys comments supporting a near-total inheritance tax have drawn sharp criticism, with some traders calling for a boycott of United. The discussion also focuses on the quarterly earnings report and recent share weakness, with traders divided between bearish concerns and potential upside if results and guidance reassure investors.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound in the Nasdaq-100 after a sharp AI-related selloff is driving attention, with traders pointing to strength in semiconductors and megacaps ahead of major technology earnings. The community is divided over whether the bounce signals a recovery or is a bull trap, amid continuing concerns about AI spending and market weakness beneath the headline indexes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX for Program Designed to Treat Friedreich Ataxia

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX for Program Designed to Treat Friedreich Ataxia Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX for Program Designed to Treat Friedreich AtaxiaPR NewswireNEW YORK, Sept. 23, 2026 NEW YORK, Sept. 23, 2026...

Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.read more...

Lexeo Therapeutics Signs Series Of Strategic Transactions To Expand Presence In Friedreich Ataxia

(RTTNews) - Lexeo Therapeutics, Inc. (LXEO), a clinical stage company, announced Tuesday a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including the signing of a definitive agreement to acquire private clinical stage company Mantle Therapeut...

What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple

What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple...

Why Is Lexeo Therapeutics Stock Gaining Monday?

Lexeo Therapeutics stock jumps as LX2006 pivotal trial moves forward, with SUNRISE-FA 2 enrollment set to begin in June 2026.read more...

Lexeo Therapeutics (LXEO) Expected to Announce Quarterly Earnings on Monday

Lexeo Therapeutics (NASDAQ:LXEO) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-lexeo-therapeutics-inc-stock...

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one...

Lexeo Therapeutics (NASDAQ:LXEO) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen cut Lexeo Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2%  - Should You Buy?

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2% - Here's What Happened...

Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $312,950.00 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 55,000 shares of the company's stock in a transaction on Monday, April 6th. The stock was sold at an average...

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Lexeo Therapeutics Inc.

Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In

Equity

Bearish Sentiment

Lexeo Therapeutics shares rose to an 11-month high on Tuesday following a series of analyst upgrades that have rekindled investor interest in the biotech’s gene therapy LX2006 for heart problems associated with Friedreich’s ataxia.The rally came after Lexeo said the U.S. Food and Drug Administration has expressed willingness to consider an accelerated approval pathway for LX2006. Such a move would allow Lexeo to combine data from its current early-stage studies with results from an ongoing pivotal trial, potentially reducing the time to commercialization.Leerink Partners lifted the firm’s price target to $20 from $9 and reiterated an 'Outperform' rating, noting that the FDA’s willingness to pool data from the ongoing Phase I/II SUNRISE-FA and pivotal studies represents “regulatory flexibility and a relatively straightforward path to approval.”&nbsp;The brokerage stated that the FDA’s decision to assess the left ventricular mass index (LVMI), the therapy’s key cardiac endpoint, earlier than planned could accelerate timelines. Additionally, further clinical data show dose-dependent, durable LVMI reductions and clean safety profiles.H.C. Wainwright raised its price target to $15 from $9 and maintained a 'Buy' rating, saying the FDA feedback improves the probability of approval to 50% from 40%. The firm also advanced its expected commercial launch to 2028 from 2030, pointing to a faster and smaller pivotal trial.Chardan followed with an increase to $17 from $15, also keeping a 'Buy' rating. The firm stated that the FDA’s decision to allow the pooling of Phase I/II and pivotal data supports the potential for accelerated approval, while updated results showed “sustained and dose-dependent improvements” in cardiac measures.The bullish revisions followed Lexeo’s announcement that the FDA was open to a Biologics License Application (BLA) that combines data from its Phase I/II studies with new pivotal data to support accelerated approval. The agency also agreed to assess LVMI improvements earlier than 12 months.Interim results from the ongoing LX2006 trials showed encouraging efficacy, with participants who had abnormal heart mass at baseline achieving an average 18% reduction in LVMI at six months and 23% at 12 months, well above the FDA’s 10% improvement threshold.&nbsp;Neurological function also improved as measured by patients' scores on the modified Friedreich Ataxia Rating Scale (mFARS) and reductions in cardiac biomarkers, including troponin I and lateral wall thickness. The therapy was well tolerated, with no serious adverse events. The company plans to initiate the pivotal study in the first half of 2026, pending completion of final protocol and manufacturing comparability reviews.LX2006 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations, among others, and is part of the FDA’s CMC Development and Readiness Pilot (CDRP) program. The company expects the therapy to advance into its pivotal stage within the next year and believes the new framework could bring approval two years earlier than previously projected.On Stocktwits, retail sentiment for Lexeo was ‘extremely bullish’ amid a 6,200% surge in 24-hour message volume.One user called the FDA update a major win but warned of a dilution risk, noting that Lexeo’s $75 million shelf registration and recent $80 million private placement could lead to a share sale if the stock continues to rise. They said it’s a typical biotech setup with big news, big move, then dilution.<stembedurl>https://stocktwits.com/Jamesnewbie/message/631275401</stembedurl>Another user took a more upbeat tone, suggesting a rapid rally ahead, stating that a swift move to $20 could be on the way.&nbsp;<stembedurl>https://stocktwits.com/kpop1/message/631309344</stembedurl><a href="https://stocktwits.com/symbol/LXEO">Lexeo’s stock</a> has risen 27% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Lexeo’s stock (LXEO) has risen 27% so far in 2025. (Photo credit: Getty Images)

Analysts raised price targets and boosted approval odds after the FDA signaled support for a faster review process, citing strong safety and efficacy data in early trials of Lexeo’s treatment for Friedreich’s ataxia–related heart disease.

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$2.76
Prev Close	$2.64
Open	$2.65
Dividend Yield	0.00%
50-Day Moving Average	$4.11
Beta	1.96
Avg. Volume	1.43M
PE Ratio	-2.38

52-Week High	$10.99
52-Week Low	$2.55
Market Capitalization	$216.71M
EPS (Annual)	-$1.86
Price to Book	0.92
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

LXEO Fundamentals